151 related articles for article (PubMed ID: 18289088)
1. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor.
Marriott KS; Huffman JW
Curr Top Med Chem; 2008; 8(3):187-204. PubMed ID: 18289088
[TBL] [Abstract][Full Text] [Related]
2. CB2 receptor ligands.
Huffman JW
Mini Rev Med Chem; 2005 Jul; 5(7):641-9. PubMed ID: 16026310
[TBL] [Abstract][Full Text] [Related]
3. The search for selective ligands for the CB2 receptor.
Huffman JW
Curr Pharm Des; 2000 Sep; 6(13):1323-37. PubMed ID: 10903395
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
Marriott KS; Huffman JW; Wiley JL; Martin BR
Bioorg Med Chem; 2006 Apr; 14(7):2386-97. PubMed ID: 16321538
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor.
Huffman JW; Bushell SM; Joshi SN; Wiley JL; Martin BR
Bioorg Med Chem; 2006 Jan; 14(1):247-62. PubMed ID: 16165365
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.
Huffman JW; Zengin G; Wu MJ; Lu J; Hynd G; Bushell K; Thompson AL; Bushell S; Tartal C; Hurst DP; Reggio PH; Selley DE; Cassidy MP; Wiley JL; Martin BR
Bioorg Med Chem; 2005 Jan; 13(1):89-112. PubMed ID: 15582455
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes.
Huffman JW; Padgett LW
Curr Med Chem; 2005; 12(12):1395-411. PubMed ID: 15974991
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242.
Mancini I; Brusa R; Quadrato G; Foglia C; Scandroglio P; Silverman LS; Tulshian D; Reggiani A; Beltramo M
Br J Pharmacol; 2009 Sep; 158(1):382-91. PubMed ID: 19552692
[TBL] [Abstract][Full Text] [Related]
9. 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor.
Huffman JW; Bushell SM; Miller JR; Wiley JL; Martin BR
Bioorg Med Chem; 2002 Dec; 10(12):4119-29. PubMed ID: 12413866
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice.
Curto-Reyes V; Boto T; Hidalgo A; Menéndez L; Baamonde A
Eur J Pharmacol; 2011 Oct; 668(1-2):184-9. PubMed ID: 21771590
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands.
Worm K; Dolle RE
Curr Pharm Des; 2009; 15(29):3345-66. PubMed ID: 19860684
[TBL] [Abstract][Full Text] [Related]
12. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.
Atwood BK; Wager-Miller J; Haskins C; Straiker A; Mackie K
Mol Pharmacol; 2012 Feb; 81(2):250-63. PubMed ID: 22064678
[TBL] [Abstract][Full Text] [Related]
13. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor.
Huffman JW; Mabon R; Wu MJ; Lu J; Hart R; Hurst DP; Reggio PH; Wiley JL; Martin BR
Bioorg Med Chem; 2003 Feb; 11(4):539-49. PubMed ID: 12538019
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB₁ and CB₂ receptors.
Uchiyama N; Kikura-Hanajiri R; Goda Y
Chem Pharm Bull (Tokyo); 2011; 59(9):1203-5. PubMed ID: 21881274
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
Wiley JL; Smith VJ; Chen J; Martin BR; Huffman JW
Bioorg Med Chem; 2012 Mar; 20(6):2067-81. PubMed ID: 22341572
[TBL] [Abstract][Full Text] [Related]
17. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.
Poso A; Huffman JW
Br J Pharmacol; 2008 Jan; 153(2):335-46. PubMed ID: 17982473
[TBL] [Abstract][Full Text] [Related]
18. Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK.
Schmuhl E; Ramer R; Salamon A; Peters K; Hinz B
Biochem Pharmacol; 2014 Feb; 87(3):489-501. PubMed ID: 24304686
[TBL] [Abstract][Full Text] [Related]
19. A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
Fichera M; Cruciani G; Bianchi A; Musumarra G
J Med Chem; 2000 Jun; 43(12):2300-9. PubMed ID: 10882356
[TBL] [Abstract][Full Text] [Related]
20. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
